Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

Investigating Exercise as a Form of Therapy in Type 1 Myotonic Dystrophy

FY 2022-23

Summary
Myotonic dystrophy 1 (DM1) is a multisystemic neuromuscular disease that afflicts approximately 1/8500 people worldwide. The disease is caused by an autosomal dominant CUG expanded (CUG-exp) repeat found in the 3' region of the dystrophia myotonica protein kinase (DMPK) gene. In patients the disease can present with skeletal muscle atrophy, weakness, myotonia and insulin resistance. These repeats cause a stable hairpin loop of the RNA which leads to a dysregulation of crucial RNA binding proteins (RNABPs), musclebind-like 1 (MBNL1) and CUG-binding protein 1 (CUGBP1). These perturbed RNABPs contribute to mis-splicing events in pre-mRNA, leading to DM1 symptoms. The insulin receptor (IR) gene is an example of a gene that is aberrantly spliced and thus contributes to insulin resistance in DM1 patients. Additionally, insulin resistance in DM1 is in part due to dysregulated activity of downstream IR intracellular targets. Further, dyregulated IR signaling contributes to muscle atrophy in DM1. In type 2 diabetes (TD2), a disease that is characterized by IR resistance, exercise is employed as a therapeutic means for improving IR sensitivity. Although this therapeutic intervention has been studied in the context of TD2, it is yet to be characterized in DM1. Thus, I will investigate this aberrant signalling pathway and how exercise can serve as a potential means for treating DM1 disease progression. My first aim will look at the predicted IR downstream proteins that are significantly perturbed using Qiagen’s Ingenuity Pathway Analysis bioinformatic tool. My second aim will search for the dysregulated IR signaling events in an induced pluripotent stem cell model of DM1. My third aim will look at how exercise in HSA-LR mice, a DM1 model, impacts IR signalling.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
487202
Name
Adjei-Afriyie Yaw O
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating Exercise as a Form of Therapy in Type 1 Myotonic Dystrophy
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Atrophy; Cell Signalling; Disease; Dystrophy; Exercise; Insulin; Insulin Resistance; Myotonia; Neuromuscular; Weakness
Abstract
Myotonic dystrophy 1 (DM1) is a multisystemic neuromuscular disease that afflicts approximately 1/8500 people worldwide. The disease is caused by an autosomal dominant CUG expanded (CUG-exp) repeat found in the 3' region of the dystrophia myotonica protein kinase (DMPK) gene. In patients the disease can present with skeletal muscle atrophy, weakness, myotonia and insulin resistance. These repeats cause a stable hairpin loop of the RNA which leads to a dysregulation of crucial RNA binding proteins (RNABPs), musclebind-like 1 (MBNL1) and CUG-binding protein 1 (CUGBP1). These perturbed RNABPs contribute to mis-splicing events in pre-mRNA, leading to DM1 symptoms. The insulin receptor (IR) gene is an example of a gene that is aberrantly spliced and thus contributes to insulin resistance in DM1 patients. Additionally, insulin resistance in DM1 is in part due to dysregulated activity of downstream IR intracellular targets. Further, dyregulated IR signaling contributes to muscle atrophy in DM1. In type 2 diabetes (TD2), a disease that is characterized by IR resistance, exercise is employed as a therapeutic means for improving IR sensitivity. Although this therapeutic intervention has been studied in the context of TD2, it is yet to be characterized in DM1. Thus, I will investigate this aberrant signalling pathway and how exercise can serve as a potential means for treating DM1 disease progression. My first aim will look at the predicted IR downstream proteins that are significantly perturbed using Qiagen’s Ingenuity Pathway Analysis bioinformatic tool. My second aim will search for the dysregulated IR signaling events in an induced pluripotent stem cell model of DM1. My third aim will look at how exercise in HSA-LR mice, a DM1 model, impacts IR signalling.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Adjei-Afriyie, Yaw O
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~